These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28678285)

  • 1. New pH-responsive gemini lipid derived co-liposomes for efficacious doxorubicin delivery to drug resistant cancer cells.
    Moitra P; Kumar K; Sarkar S; Kondaiah P; Duan W; Bhattacharya S
    Chem Commun (Camb); 2017 Jul; 53(58):8184-8187. PubMed ID: 28678285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells.
    Xia Y; Fang M; Dong J; Xu C; Liao Z; Ning P; Zeng Q
    Colloids Surf B Biointerfaces; 2018 Oct; 170():514-520. PubMed ID: 29960952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacious anticancer drug delivery mediated by a pH-sensitive self-assembly of a conserved tripeptide derived from tyrosine kinase NGF receptor.
    Moitra P; Kumar K; Kondaiah P; Bhattacharya S
    Angew Chem Int Ed Engl; 2014 Jan; 53(4):1113-7. PubMed ID: 24338837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photoresponsive transformation from spherical to nanotubular assemblies: anticancer drug delivery using macrocyclic cationic gemini amphiphiles.
    Dey S; Chatterjee S; Patel A; Pradhan N; Srivastava D; Patra N; Bhattacharyya A; Manna D
    Chem Commun (Camb); 2021 May; 57(38):4646-4649. PubMed ID: 33881081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect.
    Ahmed KS; Changling S; Shan X; Mao J; Qiu L; Chen J
    J Liposome Res; 2020 Sep; 30(3):285-296. PubMed ID: 31223044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy.
    Kang XJ; Wang HY; Peng HG; Chen BF; Zhang WY; Wu AH; Xu Q; Huang YZ
    Acta Pharmacol Sin; 2017 Jun; 38(6):885-896. PubMed ID: 28479604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
    Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J
    Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
    Obata Y; Tajima S; Takeoka S
    J Control Release; 2010 Mar; 142(2):267-76. PubMed ID: 19861141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
    Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
    Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual location stimuli-responsive degradation strategy of block copolymer nanocarriers for accelerated release.
    Chan N; Khorsand B; Aleksanian S; Oh JK
    Chem Commun (Camb); 2013 Sep; 49(68):7534-6. PubMed ID: 23863915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin and chloroquine coencapsulated liposomes: preparation and improved cytotoxicity on human breast cancer cells.
    Qiu L; Yao M; Gao M; Zhao Q
    J Liposome Res; 2012 Sep; 22(3):245-53. PubMed ID: 22607110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
    Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
    Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural tripeptide capped pH-sensitive gold nanoparticles for efficacious doxorubicin delivery both in vitro and in vivo.
    Kumar K; Moitra P; Bashir M; Kondaiah P; Bhattacharya S
    Nanoscale; 2020 Jan; 12(2):1067-1074. PubMed ID: 31845927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacious Doxorubicin Delivery Using Glutathione-Responsive Hollow Non-phospholipid Vesicles Bearing Lipoyl Cholesterols.
    Kumar K; Yadav L; Kondaiah P; Chaudhary S
    ChemMedChem; 2019 Sep; 14(18):1633-1640. PubMed ID: 31359601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles.
    Pilapong C; Keereeta Y; Munkhetkorn S; Thongtem S; Thongtem T
    Colloids Surf B Biointerfaces; 2014 Jan; 113():249-53. PubMed ID: 24103503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent.
    Miatmoko A; Kawano K; Yoda H; Yonemochi E; Hattori Y
    J Liposome Res; 2017 Jun; 27(2):99-107. PubMed ID: 26982164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of mono- and multi-hydroxyl low toxicity pH-sensitive cationic lipids for drug delivery.
    Zhao Z; Yao W; Wang N; Liu C; Zhou H; Chen H; Qiao W
    Eur J Pharm Sci; 2019 May; 133():69-78. PubMed ID: 30914360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.